Stratec (SBS) Q4 2024 earnings summary

Executive summary

• 2024 was marked by margin improvements ahead of expectations, strong cash flow, and operational strengthening despite challenges such as auditor rotation, business-related obsolescences, and changes in partner cooperation processes.

• The business model, focused on technology co-development and lifecycle management, helped mitigate lingering COVID-19 effects and manage elevated inventory levels.

• Customers prioritized maintenance and development over new instrument placements, resulting in higher development revenues and key milestones in transfusion diagnostics and immunodiagnostics.

• Strengthened presence in the US, Europe, and Asia-Pacific, with initial sales synergies from the Natech acquisition.

• Proposed dividend increase to €0.60 per share for fiscal year 2024.

Financial highlights

• Sales reached €257.6 million, down 2.7%–4.7% year-over-year, mainly due to new accounting principles; underlying decline was minimal.

• Adjusted EBIT margin improved by 180 bps to 13.0%; strategic margin up 250 bps to 19.1%.

• Adjusted EBIT was €33.5 million; adjusted EBITDA rose 9.8% to €49.2 million.

• Adjusted EPS increased to €1.69, up 8.3%; adjusted net income grew 7.8% to €20.5 million.

• Gross margin improved by 440 bps year-over-year to 29.7%.

• Cash flow from operating activities rose to €48.7 million; free cash flow turned positive at €42.7 million.

• Equity ratio increased to 54.5%; net debt/adjusted EBITDA improved to 1.8x.

Outlook and guidance

• 2025 sales expected to grow in the low to mid single-digit percentage range (constant currency), with Q1 2025 sales around €60 million.

• Adjusted EBIT margin guidance for 2025 is 10–12%, reflecting lower high-margin development/service contributions.

• Investments in tangible and intangible assets targeted at 8–10% of sales, with increased IT budget for 2025.

• Focus remains on cost visibility, procurement improvements, inventory efficiency, and expansion in high-sensitivity immunoassays and advanced imaging.